Dr. Feehery joined Certara in June, 2019 as CEO. Dr. Feehery joins Certara from DuPont, where he has served since 2013 as president of DuPont Industrial Biosciences, a $2.2 billion global biotechnology business which experienced significant growth and profitability under his leadership. In that role, he had full P&L responsibility for 3,000 people, including 500 R&D staff, 20 manufacturing plants, and worldwide marketing and sales across multiple markets. He joined DuPont in 2002 and has prior experience in venture capital and as a consultant for the Boston Consulting Group.
Dr. Feehery also serves as a board member for West Pharmaceutical Services (NYSE: WST), a manufacturer of packing components and delivery systems for pharmaceutical, biotech and medical device companies.
Dr. Feehery holds both a PhD in chemical engineering and an MBA from MIT. He was a Churchill Scholar at Cambridge University, and received his BSE in chemical engineering from the University of Pennsylvania. His doctorate, awarded while he was the recipient of a National Science Foundation Fellowship, involved developing software and mathematical methods for modeling complex systems.
Rob Aspbury, PhD, is the President of Certara’s Simcyp division. Prior to this appointment, he served as Simcyp’s Chief Operating Officer. Simcyp provides Population-based Pharmacokinetic Modeling which is used during the drug development process. These software platforms include Quantitative Systems Pharmacology (QSP), Quantitative Systems Toxicology and Safety (QSTS) and physiologically-based pharmacokinetic (PBPK) technology.
Dr. Aspbury brings more than 17 years’ commercial and scientific leadership experience with Covance to Certara. Dr. Aspbury was appointed Global Finance Director for Covance’s Clinical Pharmacology Services Division in 2003 and was rapidly promoted within the division to Managing Director, then Vice President, Europe, and later Vice President and General Manager, Global. His most recent appointment was Vice President of Covance Strategic Solutions, Biosimilars.
Dr. Aspbury earned a doctorate in biochemistry from the University of Liverpool in 1995. He is also a chartered accountant.
Ms. Choe is Certara’s Chief Strategy and Marketing Officer where she is responsible for spearheading strategic planning and all aspects of Certara’s marketing efforts, including branding, integrated marketing, market development, and market research. Previously, Jieun served as Certara’s Senior Vice President of Strategic Ventures where she developed and executed innovative, strategic initiatives for the company in collaboration with business units and key opinion leaders. She specializes in consumer insights and developing and implementing differentiated business strategies to position companies for growth.
Before joining Certara in 2016, Ms. Choe was Chief Marketing Officer at Triumph Learning and prior to that Executive Director of Marketing at Kaplan’s Precollege Division. She has also held strategic planning and product management positions at Guidant and Boston Scientific. Jieun earned her Bachelor of Arts degree in Public Policy and Economics from Stanford University and an MBA at Stanford University Graduate School of Business.
Mr. Hovde brings more than 20 years of product development, marketing, sales, and general management leadership to his work with Certara’s customers and partners. Prior to his current role, Hovde held a number of leadership positions in several innovative technology companies, including Entelos and Fast Track Systems (now Medidata Solutions). Prior to entering the R&D technology and services industry, he held leadership positions in commercial banking and management consulting.
Hovde is an author and speaker on issues facing R&D management. He serves on the finance committee of the Association of Clinical Pharmacology and Therapeutics. He holds a B.S. in economics from the Wharton School of the University of Pennsylvania and an M.B.A. from Harvard Business School.
Thomas Kerbusch, PhD, is the Chief Growth Officer of Certara. In his role, Thomas drives integrated growth opportunities with a special focus on Certara Key Account Management and client relations. Thus, he assures delivery of integrated offerings in services and software through focused commercialization, marketing, and sales for our clients and key growth markets (e.g. APAC).
Throughout his career, Thomas has greatly enjoyed working with talented scientists and business professionals to make a real difference in drug development and patient access to new treatment options by implementing novel and creative model-based technology-enabled approaches. During the last two decades, Thomas has contributed to the development and approval of numerous drugs in a wide range of therapeutic indications.
Previously, Thomas made his mark on Certara’s growth as divisional President overseeing the growth of Certara’s Integrated Drug Development services and Pharmacometrics Software teams and integration of the Value & Access services and Software acquisitions. Prior to joining Certara in 2014, Thomas was a leader in the integration of M&S capabilities at Organon/Schering-Plough and Merck/MSD upon merger of these companies.
Thomas received his undergraduate education in Biopharmaceutical Sciences at Leiden University and Georgetown University. He obtained his PhD in Clinical Pharmacology at the Netherlands Cancer Institute. In 2001, he conducted postdoctoral research on PK/PD M&S at Uppsala University, Sweden. Thomas got introduced to implementing M&S in an industry setting at Pfizer, UK, 2002-2006, leaving as a Director of clinical PK/PD M&S to join Organon in the Netherlands, to lead their PK/PD group. Subsequently Thomas headed the PK/PD and Pharmacometrics group at Schering-Plough (2008-2010) and held various leadership roles in Merck/MSD as Executive Director Quantitative Pharmacology & Pharmacometrics (2010-2014). He was also part of the management team of the Dutch MSD development site. He has (co-) authored over 40 peer-reviewed publications.
Prior to joining Certara, Dr. Mandema founded Quantitative Solutions in 2005 after spending more than 18 years in clinical pharmacology research and consulting. In addition, he was Senior Vice President and Chief Scientific Officer at Pharsight from 1996 to 2004. Mandema joined Pharsight in its infancy and played a critical role in its growth into a public company whose modeling and simulation services are highly regarded across the industry. At Pharsight, he was responsible for the scientific leadership of the company, the development of novel methods and the implementation of these methods in new software products. He pioneered the building and modeling of clinical trial outcome databases in evaluating product profiles across competing drugs. Before Pharsight, Mandema was Director of New Products Discovery at ALZA Corporation, responsible for defining new product opportunities for ALZA’s delivery technologies.
Mandema’s research interests are applying modeling and simulation to optimize treatment strategies, trial designs, and drug development decision-making. He has published extensively and received several awards for his academic contributions, including the Tanabe Young Investigators Award from the American College of Clinical Pharmacology and the Leon Goldberg Young Investigator Award from the American Society for Clinical Pharmacology and Therapeutics. Mandema started his professional career as an assistant professor of pharmaceutical sciences at the department of anesthesia, Stanford University School of Medicine. He received his PhD (cum laude) from the division of pharmacology at the Center for Bio-pharmaceutical Sciences, University of Leiden and his MS (cum laude) from the School of Pharmacy, University of Utrecht, the Netherlands.
Leif E. Pedersen is a seasoned software industry executive with more than 35 years of experience delivering software solutions across multiple industries and a proven track record of delivering high value customer-driven innovative software solutions. Mr. Pedersen was most recently senior operating partner at SymphonyAI responsible for portfolio companies across life sciences, healthcare, industrial, and defense industries.
Previously, Mr. Pedersen was chief executive officer of BIOVIA at Dassault Systèmes, a scientific software brand providing solutions for life and material sciences industries. Before joining BIOVIA, Mr. Pedersen served as executive vice president at Innovative Interfaces; senior vice president at Accelrys Software, Inc.; and vice president at Siemens Corporation. Mr. Pedersen has also held executive leadership positions with Vignette Corporation, Novell Inc., CA Technologies, and Oracle Corporation.
Dr. Rayner is President of Certara’s Integrated Drug Development and Strategic Consulting Services. In this capacity, he supports a global team of clinical and quantitative pharmacologists, pharmacometricans, regulatory strategy and drug development scientists who create value for clients across the drug development ecosystem and ultimately accelerate patients’ access to medicines.
Craig has extensive global experience in early and late development of therapeutics, regulatory interaction experience with all major global health authorities, multiple filings and accountability for numerous due diligences, active support of negotiations, deal making and integration activities.
Previously, Craig was the Co-founder and CEO of d3 Medicine. Prior to that, Craig’s appointments included leadership roles in Clinical Pharmacology and Early development (Roche), Clinical development (CSL-Behring), in Business Development/Licensing as Global Due Diligence Director (Roche), and in clinical pharmacology and infectious disease research (Monash University).
Craig holds an Adjunct Associate Professorship in Pharmaceutical Science (Monash University), is a Distinguished Alumni of the Faculty of Pharmacy and Pharmaceutical Sciences (Monash University), has broadly published in clinical pharmacology and also infectious diseases.
Professor Rostami is the Senior Vice President of Research & Development and Chief Scientific Officer at Certara. His mission is to ensure that the latest scientific advances in the field of biosimulation are incorporated into all of the drug development efforts by various pharmaceutical companies. He joined Certara in 2012 as a co-founder of Simcyp Limited (a University of Sheffield spin-off which was acquired by Certara),
Amin is also a Professor of Systems Pharmacology and the Director of the Centre for Applied Pharmacokinetic Research (CAPKR) at the University of Manchester. He has an active program of training PhD students involving proteomics, physiologically-based pharmacokinetics and pharmacodynamics, and precision dosing within CAPKR, and numerous graduates from his team are currently active in pharmaceutical industry or academic research.
Professor Rostami was the first full Professor appointed with the title of Systems Pharmacology in 2007 whilst working at the University of Sheffield, He has authored/co-authored over 250 highly cited articles (>12,500 citations, H-Factor >55). In 2017, he was listed by ISI as one of the world’s most highly cited researchers (under ‘Pharmacology & Toxicology’). He was a founding editor of Pharmacometrics and System Pharmacology and has served on the Editorial Boards of several other journals (e.g. BDD, CDM, CPDD, DMPK, JPKPD, BJCP). Professor Rostami is renowned for his contribution to translational modelling (e.g. PBPK) and has been an invited speaker at over 200 international and national meetings, in addition to leading numerous workshops in the area of IVIVE- PBPK linked models.
Rich Traynor serves as Certara’s General Counsel. Rich has been practicing law for over 20 years at publicly-traded and privately-held life sciences companies. Rich began his legal career in Dallas, Texas at the law firm of Jenkens & Gilchrist. In 2002, he moved back to his home state of New Jersey, where he became a partner at Porzio, Bromberg & Newman. In 2009, Rich joined LifeCell Corporation, where he became the Chief Legal and Compliance Officer. In that role, Rich served on the executive leadership team and was responsible for all legal and compliance matters, including licensing and acquisitions, buy- and sell-side contracting, dispute resolution, and enterprise risk assessment and mitigation. While at LifeCell, Rich also had responsibility for legal matters related to the commercial-side of LifeCell’s parent company, Acelity, in North and Latin America. Following a successful sale of the LifeCell business to Allergan, Rich joined Edge Therapeutics, a clinical stage biotechnology company, where he had broad responsibilities involving all legal matters impacting the Edge business, including negotiating complex commercial transactions, corporate governance, and developing corporate policies and procedures.
Rich graduated magna cum laude from the University of Notre Dame, where he earned a degree in the Program of Liberal Studies, and he received his law degree from the University of Virginia School of Law.